Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients.

Reidenberg BE, Wanner C, Polsky B, Castanheira M, Shelip A, Stalleicken D, Pfaffle AE.

Eur J Clin Microbiol Infect Dis. 2017 Dec 6. doi: 10.1007/s10096-017-3157-7. [Epub ahead of print]

PMID:
29214504
2.

Pentaerythritol Tetranitrate In Vivo Treatment Improves Oxidative Stress and Vascular Dysfunction by Suppression of Endothelin-1 Signaling in Monocrotaline-Induced Pulmonary Hypertension.

Steven S, Oelze M, Brandt M, Ullmann E, Kröller-Schön S, Heeren T, Tran LP, Daub S, Dib M, Stalleicken D, Wenzel P, Münzel T, Daiber A.

Oxid Med Cell Longev. 2017;2017:4353462. doi: 10.1155/2017/4353462. Epub 2017 Feb 28.

3.

Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: a 12-week, randomized, double-blind, placebo-controlled trial.

Münzel T, Meinertz T, Tebbe U, Schneider HT, Stalleicken D, Wargenau M, Gori T, Klingmann I; CLEOPATRA Study Investigators.

Eur Heart J. 2014 Apr;35(14):895-903. doi: 10.1093/eurheartj/eht384. Epub 2013 Sep 26.

4.

Chronic protection against ischemia and reperfusion-induced endothelial dysfunction during therapy with different organic nitrates.

Lisi M, Oelze M, Dragoni S, Liuni A, Steven S, Luca MC, Stalleicken D, Münzel T, Laghi-Pasini F, Daiber A, Parker JD, Gori T.

Clin Res Cardiol. 2012 Jun;101(6):453-9. doi: 10.1007/s00392-012-0412-x.

PMID:
22298019
5.

Monitoring white blood cell mitochondrial aldehyde dehydrogenase activity: implications for nitrate therapy in humans.

Wenzel P, Schulz E, Gori T, Ostad MA, Mäthner F, Schildknecht S, Göbel S, Oelze M, Stalleicken D, Warnholtz A, Münzel T, Daiber A.

J Pharmacol Exp Ther. 2009 Jul;330(1):63-71. doi: 10.1124/jpet.108.149716. Epub 2009 Apr 3.

6.

Potency and in vitro tolerance of organic nitrates: partially denitrated metabolites contribute to the tolerance-devoid activity of pentaerythrityl tetranitrate.

Koenig A, Lange K, Konter J, Daiber A, Stalleicken D, Glusa E, Lehmann J.

J Cardiovasc Pharmacol. 2007 Jul;50(1):68-74.

PMID:
17666918
7.

Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates.

Wenzel P, Oelze M, Coldewey M, Hortmann M, Seeling A, Hink U, Mollnau H, Stalleicken D, Weiner H, Lehmann J, Li H, Förstermann U, Münzel T, Daiber A.

Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1729-35. Epub 2007 May 31.

8.

Mitochondrial oxidative stress and nitrate tolerance--comparison of nitroglycerin and pentaerithrityl tetranitrate in Mn-SOD+/- mice.

Mollnau H, Wenzel P, Oelze M, Treiber N, Pautz A, Schulz E, Schuhmacher S, Reifenberg K, Stalleicken D, Scharffetter-Kochanek K, Kleinert H, Münzel T, Daiber A.

BMC Cardiovasc Disord. 2006 Nov 8;6:44.

9.

Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates.

Daiber A, Oelze M, Coldewey M, Bachschmid M, Wenzel P, Sydow K, Wendt M, Kleschyov AL, Stalleicken D, Ullrich V, Mülsch A, Münzel T.

Mol Pharmacol. 2004 Dec;66(6):1372-82. Epub 2004 Aug 26.

10.

Endothelial protection by pentaerithrityl trinitrate: bilirubin and carbon monoxide as possible mediators.

Oberle S, Abate A, Grosser N, Hemmerle A, Vreman HJ, Dennery PA, Schneider HT, Stalleicken D, Schröder H.

Exp Biol Med (Maywood). 2003 May;228(5):529-34.

PMID:
12709581
11.

[Electrochemical reduction of pentaerythrityltetranitrate (PETN) and metabolites].

Hess U, Brosig H, König G, Stoeter M, Stalleicken D.

Pharmazie. 2002 Jul;57(7):460-4. German.

PMID:
12168525
12.

Heme oxygenase-1 induction may explain the antioxidant profile of pentaerythrityl trinitrate.

Oberle S, Abate A, Grosser N, Vreman HJ, Dennery PA, Schneider HT, Stalleicken D, Schröder H.

Biochem Biophys Res Commun. 2002 Feb 8;290(5):1539-44.

PMID:
11820797
13.

[Experimental study of the effect of pentaerythritol tetranitrate in acute myocardial infarct].

Hohlfeld T, Schütz A, Vogel YC, Stalleicken D, Braun M, Schrör K.

Herz. 2000 Nov;25(7):694-702. German.

PMID:
11141679
14.
15.

Formation of reactive oxygen species by pentaerithrityltetranitrate and glyceryl trinitrate in vitro and development of nitrate tolerance.

Dikalov S, Fink B, Skatchkov M, Stalleicken D, Bassenge E.

J Pharmacol Exp Ther. 1998 Aug;286(2):938-44.

16.

Quantitative determination of pentaerythrityl tetranitrate and its metabolites in human plasma by gas chromatography/mass spectrometry.

Stalleicken D, Kuntze U, Schmid B, Hiebl R, Ring J, Michaelis K.

Arzneimittelforschung. 1997 Apr;47(4):347-52.

PMID:
9150853
17.

Pharmacokinetics and bioavailability of pentaerithrityl tetranitrate and two of its metabolites.

Weber W, Michaelis K, Luckow V, Kuntze U, Stalleicken D.

Arzneimittelforschung. 1995 Jul;45(7):781-4.

PMID:
8573222
19.

Exercise increases endothelin-1 plasma concentrations in patients with coronary artery disease: modulatory role of LDL cholesterol and of pentaerithrityltetranitrate.

Predel HG, Knigge H, Prinz U, Kramer HJ, Stalleicken D, Rost RE.

J Cardiovasc Pharmacol. 1995;26 Suppl 3:S497-501.

PMID:
8587457
20.
21.

Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine.

Kleine-Tebbe J, Josties C, Frank G, Stalleicken D, Buschauer A, Schunack W, Kunkel G, Czarnetzki B.

J Allergy Clin Immunol. 1994 Feb;93(2):494-500.

PMID:
7509820
22.

[Results of 2 multicenter therapy studies in inoperable non-small cell bronchial cancer].

Wolf M, Havemann K, Stalleicken D, Gropp C, Maasberg M, Hans K, von Bültzingslöwen F, Klasen H, Becker H, Schroeder M, et al.

Onkologie. 1988 Oct;11(5):222-31. German.

PMID:
2849078

Supplemental Content

Loading ...
Support Center